"Patient advocates are research partners. We can provide the scientific expertise; they provide the lived experience. Patients are really the ones responsible for making #ILC visible to the research community." - Dr. Mo Rimawi

Hear hear!!!
#ILCSymposium #lobmob @lobularbca.bsky.social

Dr. Karen van Baelen looked at modifiable risk factors in #ILC recurrence. Physical activity once again shown to be beneficial for #breastcancer patients! #ILCSymposium #lobmob #bcsm #exerciseismedicine

Dr. Rachel Jankowitz talks about #lobular #breastcancer in premenopausal patients. Stays say 80-85% of ILC pts are postmenopausal; 10-15% are premenopausal. BUT at UCSF, 28% of #ILC pts were premenopausal; at Penn, 35% of ILC pts were premenopausal. #ILCSymposium @lobularbca.bsky.social #lobmob

Guilford breaks down clinical management of hereditary diffuse #gastriccancer which is intense. Patients often have their stomachs removed, which comes w/ many adverse effects (& a few bennies, he noted, tongue firmly in cheek). #ILCSymposium #HDGC #lobmob #bcsm

Guilford proposes using the term hereditary diffuse gastric & #lobular #breastcancer syndrome for those w/ #CDH1 mutation since many people who survive #gastric #cancer will develop #lobularBC. #ILCSymposium @lobularbca.bsky.social @elbcc-2018.bsky.social #bcsm #lobmob

Keynote speaker Dr. Parry Guilford breaks down the similarities between #lobular #breastcancer and diffuse #gastriccancer via a hereditary #CDH1 mutation. #ILCSymposium. Good to know as we enter Hereditary Cancer Awareness Week! #bcsm @lobularbca.bsky.social

Can artificial intelligence improve subtyping of #lobular #breastcancer? A look at subtypes & the possibility of reclassifying #ILC morphology. #ILCSymposium @lobularbca.bsky.social @lobularbcuk.bsky.social

There's been "tremendous progress" in the creation of scientific models of #ILC for research -- always good for patients to hear! And more coming, per Dr. Adrien Lee. #ILCSymposium #BCSM @lobularbca.bsky.social @elbcc-2018.bsky.social @lobularbcuk.bsky.social

ILC #breastcancer lacks models. Dr. Adrien Lee talked about the development of #ILC patient derived organoids and cell lines, a project launched w/help from @fredhutch.org #lobular #BC advocate Leigh Pate, founder of @lobularbca.bsky.social, who died in 2022. #ILCSymposium. RIP and well done, Leigh!

Dr. Sherry Shen argues that #chemo is effective in patients w/#mILC in the right time, right setting. "Chemo is not something we should use up front 4 most of our patients ..." Use chemo after endocrine therapy resistance & when fast response is critical in pts 2 prevent complicatns. #ILCSymposium

Gr8 debate at the #ILCSymposium as 2 whethr #chemo is helpful or not in #metastatic CLASSICAL #lobular #breastcancer. Dr. Rebecca Shatsky argues chemo failed 3 tests in #mILC: it's not superior, not durable, not biologically matched. Chemo shld be exception, not default. @lobularbca.bsky.social

#Cancer researchers' favorite font, Comic Sans, rears its head at the #ILCSymposium. 😉 #CanSky #BCSM #funwithfonts

First up this morning, @fredhutch.org's translational researcher Dr. Kevin Cheung talking about the #metastatic "interactome" in #lobular #breastcancer #CanSky #ILCSymposium #bcsm @lobularbca.bsky.social @elbcc-2018.bsky.social @lobularbcuk.bsky.social

Great advocacy session this morning at the #ILCSymposium in San Francisco w/advocates from around the world. Here @clairehudson.bsky.social from @lobularbcuk.bsky.social talks about how to make it easier 4 #lobularBC patients to join #clinicaltrials. #CanSky #bcsm #lobmob

Great news regarding #LARC, Lobular America Research Consortium, a new research collaboration between 18 institutions across America, all digging into #nolump #lobular #breastxancer. Thank you @mjsikora.bsky.social and #racheljankowitz for leading this initiative! #CanSky #bcsm #ILCSymposium

The #ILCSymposium kicks off in San Francisco w/an advocate session led by @lobularbca.bsky.social advocates and Dr. Rita Mukhtar. #CanSky #bcsm #lobmob